ClinicalTrials.gg
CompletedNCT05513950Updated Aug 14, 2025Results posted

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).

A Phase 1 interventional study of CHF10067 starting dose -- 1000mg (Cohort A) and CHF10067 intermediate dose -- 2000mg (Cohort B) in Idiopathic Pulmonary Fibrosis, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 9 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 21 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.

Enrollment
52nd of 83
52 · median 109
Started
2023
with 7 others
Phase 1
15 of 103
none open now
Registered
73rd of 103
by date
Lead sponsor
2 of 103
Chiesi Farmaceutici S.p.A.

Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 52nd largest by enrollment of the 83 interventional ones that give a count, is one of 8 that started in 2023, is one of 15 in phase 1, and was the 73rd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug was evaluated.

Chiesi conducted this study in patients affected by idiopathic pulmonary fibrosis (IPF, a progressive and chronic lung disease). Chiesi performed this study to establish the drug doses that would be suitable for future studies (a dose finding study).

Read the detailed description

The principal aim of this study was to obtain safety and tolerability data when CHF10067 was administered intravenously as single ascending doses to subjects with IPF (a progressive and chronic lung disease). This information, together with the pharmacokinetic (PK) and immunogenicity data is part of a dose finding efforts, for future clinical studies. The effect of CHF10067 on transglutaminase 2 (TG2) levels was also investigated as an exploratory endpoint.

A sequential group, single ascending dose design has been chosen for safety reasons because CHF10067 is in the early stages of clinical development and no data in the IPF population has been collected so far. In addition, sentinel dosing was used so that in each cohort 2 subjects (1 CHF10067 and 1 placebo) was administered at least 24 hours, before the remaining 6 subjects.

The study was double-blind and placebo-controlled to avoid bias in the collection and evaluation of data during its conduct. Placebo was chosen as the comparison treatment to assess whether any observed effects are treatment-related or reflect the study conditions.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's written obtained prior to any study-related procedure.
  • Males or females, of any race, aged ≥ 40 years of age.
  • Body weight ≥ 45 kg.
  • Diagnosis of IPF as defined by current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines. Diagnosis of IPF must be within the past 5 years prior to enrolment, and in the opinion of the Investigator, has been stable for at least 3 months.
  • Subjects not receiving any IPF treatment (including subjects with previous use of antifibrotic treatment that has been stopped for at least 2 weeks prior to screening) or receiving well-tolerated standard of care approved treatments at a stable dose for at least 8 weeks prior to screening (nintedanib or pirfenidone) and it is anticipated the dose will remain unchanged throughout the study.
  • Forced vital capacity (FVC) ≥ 50% of predicted and ratio of (FEV1)/FVC ≥ 0.7 at screening.
  • Diffusing capacity of the lung for carbon monoxide (DLCO; corrected for ) ≥ 35% at screening.
  • Able to understand the study procedures and the risks involved.
  • Male and Female subjects following requirements detailed in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • History of lower respiratory tract infection within 4 weeks prior to screening and up to Day 1 of the study.
  • History of acute exacerbation of IPF within 3 months prior to screening and up to Day 1 of the study
  • Active diagnosis of lung cancer or a history of lung cancer.
  • Active cancer or a history of cancer (other than lung cancer) with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or ).
  • Infiltrative lung disease other than IPF
  • Subjects exhibiting unhealed wounds or foot ulcers or have known history of wound healing complications.
  • Chronic heart failure categorized as Class II, III, or IV; clinical diagnosis of cor pulmonale requiring specific treatment; or severe pulmonary hypertension
  • Currently receiving, or have received, a systemic , , cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved or treatment for IPF within 4 weeks prior to screening or prior to randomization.
  • Coronavirus disease-2019 (COVID-19) vaccine at least 7 days before dosing. Any systemic symptoms (e.g. myalgia, fever, chills, fatigue, etc.) after COVID-19 vaccine should subside at least 2 days before the Day 1 visit.
  • Documented COVID-19 diagnosis within the last 4 weeks or which has not resolved within 7 days prior to screening or before treatment.
  • Known intolerance and/or to any of the contained in the formulation or any other substance used in the study.
  • History of allergic or anaphylactic reaction to human, humanised, chimeric, immunoglobulins (Igs), or murine monoclonal antibodies.
  • abnormal laboratory values (clinical chemistry and haematology) at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the study results according to Investigator judgement. .
  • Pregnant or lactating women.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Test Treatment

    A single intravenous (IV) dose of CHF10067

    Biological: CHF10067 starting dose -- 1000mg (Cohort A) · Biological: CHF10067 intermediate dose -- 2000mg (Cohort B) · Biological: CHF10067 high dose -- 3000mg (Cohort C)

  • Placebo comparator
    Reference treatment

    A single dose of placebo (commercial source of 0.9% sodium chloride aqueous solution)

    Drug: Placebo

Interventions

  • BiologicalCHF10067 starting dose -- 1000mg (Cohort A)

    Intravenous administration of a starting dose of the monoclonal antibody

  • BiologicalCHF10067 intermediate dose -- 2000mg (Cohort B)

    Intravenous administration of an intermediate dose of the monoclonal antibody

  • BiologicalCHF10067 high dose -- 3000mg (Cohort C)

    Intravenous administration of a high dose of the monoclonal antibody

  • DrugPlacebo

    Intravenous administration of a physiological solution as placebo

06

What researchers measure

Primary outcomes

  1. 1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs

    Evaluate reported adverse events (AEs) and serious adverse events (SAEs). The number of subjects affected by AEs or SAEs is presented below. Please note: comprehensive summaries of AEs and SAEs are presented in section 'Adverse Events'; these include the preferred term of the AE or SAE, the number of subjects affected, and the number of events for a each preferred term.

    Time frame: From pre-dose (baseline) up to day 84.

Secondary outcomes

  1. 2_Systemic Exposure [Area Under the Concentration-time Curve From Zero to Time (AUC0-t)]

    Evaluate the area under the concentration-time curve (AUC) from zero to the last quantifiable concentration (AUC0-t) of CHF10067 after a single dose.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.

  2. 3_Area Under the Concentration-time Curve (AUC) From Zero to Infinity (AUC0-∞)

    Evaluate the area under the concentration-time curve (AUC) from zero to infinity (AUC0-∞) of CHF10067 after a single dose.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.

  3. 4_Pharmacokinetics -- Maximum Plasma Concentration (Cmax)

    Evaluate the Cmax (maximum observed concentration) after a single dose of CHF10067.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.

  4. 5_Pharmacokinetics -- Time to Maximum Observed Concentration (Tmax)

    Evaluate the time to maximum observed concentration (tmax).

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.

  5. 6_Pharmacokinetics -- Serum Concentration at the End of Infusion (Cinf)

    Evaluate serum concentration at the end of infusion (Cinf) of CHF10067.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion (up to 6 hours from the start of infusion).

  6. 7_Pharmacokinetics -- Time at the End of Infusion (Tinf)

    Evaluate the time of serum concentration at the end of infusion (Tinf). Time at the end of the infusion.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion (up to 6 hours from the start of infusion).

  7. 8_Pharmacokinetics -- Clearance (CL)

    Evaluate clearance (CL) of CHF10067.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.

  8. 9_Pharmacokinetics -- Volume of Distribution (Vz)

    Evaluate volume of distribution (Vz) CHF10067.

    Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.

  9. 10_Pharmacokinetics -- Terminal Half-life (t1/2)

    Evaluate the terminal half-life (t1/2) of CHF10067.

    Time frame: From pre-dose (baseline) up to day 84.

  10. 11_Spirometry -- Forced Expiratory Volume in the First Second (FEV1) -- Percent Predicted -- Change From Baseline

    Forced expiratory volume in the first second (FEV1) parameters, summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.

    Time frame: Pre-dose (baseline), and on 7, 28, 56, and 84 day post-dose.

  11. 12_Spirometry -- Forced Vital Capacity (FVC) -- Percent Predicted -- Change From Baseline

    Forced vital capacity (FVC) parameters will be summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.

    Time frame: Text adjusted Pre-dose (baseline), and on 7, 28, 56, and 84 day post-dose.

  12. 13_Vital Signs -- Abnormal Changes in Systolic and Diastolic Blood Pressure

    Evaluate abnormal changes in systolic and diastolic blood pressure from baseline at any post-baseline time point.

    Time frame: From pre-dose (baseline) up to day 84.

  13. 14_Immunogenicity Profile -- Anti-drug Antibody (ADA) and Neutralising Antibody (nAb).

    Evaluate the immunogenicity profile of CHF 10067 in serum, with respect to the development of anti-drug antibody (ADA) and neutralising antibody (nAb). A robust immunogenicity profile indicates the potential for the drug to trigger an immune response in patients, leading to the formation of ADAs. These antibodies can affect the drug's efficacy, safety, and pharmacokinetics. Detecting the presence of ADAs in serum samples was performed using an enzyme linked immunosorbent assay (ELISA), a validated assay method. Neutralizing Antibody (nAb) are a subset of ADAs that can interfere with the drug's therapeutic activity by blocking its binding to the target or inhibiting its downstream effects. The presence of ADAs and nAbs can affect the drug's pharmacokinetics (PK) by altering its absorption, distribution, metabolism, and excretion. This can lead to changes in drug exposure and potentially impact efficacy and safety.

    Time frame: Pre-dose (baseline), at day 14, 28, 56, 84, and in case of early termination.

07

Results

Posted Aug 14, 2025

Participant flow

For the study, 52 male and female subjects were screened 3-28 days before randomization; of these, 27 subjects were screening failures. Overall, 25 subjects were randomized; of these 1 subject (CHF 10067 3000 mg) did not receive the study medication due to technical reasons.

Participant flow — Overall Study
MilestoneCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
Started6676
Completed6666
Not completed0010
Withdrew: Not treated due to technical reasons0010

Outcome measures

Primary1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs

Evaluate reported adverse events (AEs) and serious adverse events (SAEs). The number of subjects affected by AEs or SAEs is presented below. Please note: comprehensive summaries of AEs and SAEs are presented in section 'Adverse Events'; these include the preferred term of the AE or SAE, the number of subjects affected, and the number of events for a each preferred term.

Time frame:
From pre-dose (baseline) up to day 84.
Reported as:
Count of participants · Participants
1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs
ParticipantsCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
Serious TEAE0010
Non-serious TEAE4354
AE leading to study treatment discontinuation0000
AE leading to death0000
Secondary2_Systemic Exposure [Area Under the Concentration-time Curve From Zero to Time (AUC0-t)]

Evaluate the area under the concentration-time curve (AUC) from zero to the last quantifiable concentration (AUC0-t) of CHF10067 after a single dose.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
Reported as:
Mean · day.μg/mL
2_Systemic Exposure [Area Under the Concentration-time Curve From Zero to Time (AUC0-t)]
day.μg/mLCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
2_Systemic Exposure [Area Under the Concentration-time Curve From Zero to Time (AUC0-t)]3424 ± 6477902 ± 100115592 ± 3027
Secondary3_Area Under the Concentration-time Curve (AUC) From Zero to Infinity (AUC0-∞)

Evaluate the area under the concentration-time curve (AUC) from zero to infinity (AUC0-∞) of CHF10067 after a single dose.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
Reported as:
Mean · day.μg/mL
3_Area Under the Concentration-time Curve (AUC) From Zero to Infinity (AUC0-∞)
day.μg/mLCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
3_Area Under the Concentration-time Curve (AUC) From Zero to Infinity (AUC0-∞)3450 ± 6608141 ± 111216328 ± 3245
Secondary4_Pharmacokinetics -- Maximum Plasma Concentration (Cmax)

Evaluate the Cmax (maximum observed concentration) after a single dose of CHF10067.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
Reported as:
Mean · μg/mL
4_Pharmacokinetics -- Maximum Plasma Concentration (Cmax)
μg/mLCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
4_Pharmacokinetics -- Maximum Plasma Concentration (Cmax)307 ± 43.9668 ± 1261067 ± 173
Secondary5_Pharmacokinetics -- Time to Maximum Observed Concentration (Tmax)

Evaluate the time to maximum observed concentration (tmax).

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
Reported as:
Median · hour
5_Pharmacokinetics -- Time to Maximum Observed Concentration (Tmax)
hourCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
5_Pharmacokinetics -- Time to Maximum Observed Concentration (Tmax)1.69 (1.67 to 3.67)3.78 (3.58 to 11.67)5.39 (5.35 to 7.43)
Secondary6_Pharmacokinetics -- Serum Concentration at the End of Infusion (Cinf)

Evaluate serum concentration at the end of infusion (Cinf) of CHF10067.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion (up to 6 hours from the start of infusion).
Reported as:
Mean · μg/mL
6_Pharmacokinetics -- Serum Concentration at the End of Infusion (Cinf)
μg/mLCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
6_Pharmacokinetics -- Serum Concentration at the End of Infusion (Cinf)304 ± 44.6658 ± 1381065 ± 174
Secondary7_Pharmacokinetics -- Time at the End of Infusion (Tinf)

Evaluate the time of serum concentration at the end of infusion (Tinf). Time at the end of the infusion.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion (up to 6 hours from the start of infusion).
Reported as:
Median · hour
7_Pharmacokinetics -- Time at the End of Infusion (Tinf)
hourCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
7_Pharmacokinetics -- Time at the End of Infusion (Tinf)1.68 (1.67 to 1.72)3.69 (3.58 to 3.85)5.38 (5.35 to 5.50)
Secondary8_Pharmacokinetics -- Clearance (CL)

Evaluate clearance (CL) of CHF10067.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
Reported as:
Mean · liter/day
8_Pharmacokinetics -- Clearance (CL)
liter/dayCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
8_Pharmacokinetics -- Clearance (CL)0.295 ± 0.04890.250 ± 0.03570.190 ± 0.0363
Secondary9_Pharmacokinetics -- Volume of Distribution (Vz)

Evaluate volume of distribution (Vz) CHF10067.

Time frame:
Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
Reported as:
Mean · liter
9_Pharmacokinetics -- Volume of Distribution (Vz)
literCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
9_Pharmacokinetics -- Volume of Distribution (Vz)4.93 ± 0.9695.99 ± 0.7165.21 ± 1.03
Secondary10_Pharmacokinetics -- Terminal Half-life (t1/2)

Evaluate the terminal half-life (t1/2) of CHF10067.

Time frame:
From pre-dose (baseline) up to day 84.
Reported as:
Mean · days
10_Pharmacokinetics -- Terminal Half-life (t1/2)
daysCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)
10_Pharmacokinetics -- Terminal Half-life (t1/2)11.7 ± 2.2016.8 ± 2.3219.1 ± 1.93
Secondary11_Spirometry -- Forced Expiratory Volume in the First Second (FEV1) -- Percent Predicted -- Change From Baseline

Forced expiratory volume in the first second (FEV1) parameters, summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.

Time frame:
Pre-dose (baseline), and on 7, 28, 56, and 84 day post-dose.
Reported as:
Mean · percent predicted FEV1
11_Spirometry -- Forced Expiratory Volume in the First Second (FEV1) -- Percent Predicted -- Change From Baseline
percent predicted FEV1CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
Day 73.93 ± 3.350.50 ± 2.74-0.20 ± 1.34-0.43 ± 2.60
Day 283.76 ± 3.66-0.55 ± 3.06-2.93 ± 2.81-0.55 ± 3.37
Day 563.18 ± 3.58-0.68 ± 3.54-0.75 ± 5.68-1.35 ± 2.93
Day 840.13 ± 5.570.36 ± 4.30-2.70 ± 2.93-1.40 ± 3.62
Secondary12_Spirometry -- Forced Vital Capacity (FVC) -- Percent Predicted -- Change From Baseline

Forced vital capacity (FVC) parameters will be summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.

Time frame:
Text adjusted Pre-dose (baseline), and on 7, 28, 56, and 84 day post-dose.
Reported as:
Mean · percent predicted FVC
12_Spirometry -- Forced Vital Capacity (FVC) -- Percent Predicted -- Change From Baseline
percent predicted FVCCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
Day 73.12 ± 2.24-0.90 ± 3.31-0.50 ± 2.89-0.92 ± 3.80
Day 282.70 ± 3.74-0.50 ± 2.58-3.23 ± 2.76-0.13 ± 4.10
Day 562.50 ± 1.87-1.17 ± 3.12-1.42 ± 6.55-0.90 ± 2.84
Day 84-0.72 ± 4.02-0.36 ± 3.56-1.98 ± 3.79-1.97 ± 3.22
Secondary13_Vital Signs -- Abnormal Changes in Systolic and Diastolic Blood Pressure

Evaluate abnormal changes in systolic and diastolic blood pressure from baseline at any post-baseline time point.

Time frame:
From pre-dose (baseline) up to day 84.
Reported as:
Count of participants · Participants
13_Vital Signs -- Abnormal Changes in Systolic and Diastolic Blood Pressure
ParticipantsCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
Systolic Blood Pressure Decrease From Baseline >20 mmHg3012
Systolic Blood Pressure Increase From Baseline >20 mmHg1012
Diastolic Blood Pressure Decrease From Baseline >10 mmHg3554
Diastolic Blood Pressure Increase From Baseline >10 mmHg2223
Secondary14_Immunogenicity Profile -- Anti-drug Antibody (ADA) and Neutralising Antibody (nAb).

Evaluate the immunogenicity profile of CHF 10067 in serum, with respect to the development of anti-drug antibody (ADA) and neutralising antibody (nAb). A robust immunogenicity profile indicates the potential for the drug to trigger an immune response in patients, leading to the formation of ADAs. These antibodies can affect the drug's efficacy, safety, and pharmacokinetics. Detecting the presence of ADAs in serum samples was performed using an enzyme linked immunosorbent assay (ELISA), a validated assay method. Neutralizing Antibody (nAb) are a subset of ADAs that can interfere with the drug's therapeutic activity by blocking its binding to the target or inhibiting its downstream effects. The presence of ADAs and nAbs can affect the drug's pharmacokinetics (PK) by altering its absorption, distribution, metabolism, and excretion. This can lead to changes in drug exposure and potentially impact efficacy and safety.

Time frame:
Pre-dose (baseline), at day 14, 28, 56, 84, and in case of early termination.
Reported as:
Count of participants · Participants
14_Immunogenicity Profile -- Anti-drug Antibody (ADA) and Neutralising Antibody (nAb).
ParticipantsCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
1_Baseline ADA positive0000
2_ADA prevalence1000
3_ADA incidence (ADA+)1000
4_Duration of ADA Persistently positive ADA0000
5_Duration of ADA Transiently positive ADA1000
6_Treatment-boosted ADA0000
7_nAb positive at any visit1000

Adverse events

Collected over Adverse events (AE) were reported from the time of patient informed consent signature until subject's study participation ended (day 84 or early withdrawal).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CHF 10067 1000 mg (Test Treatment)0/6 (0%)0/6 (0%)4/6 (66.7%)
CHF 10067 2000 mg (Test Treatment)0/6 (0%)0/6 (0%)3/6 (50%)
CHF 10067 3000 mg (Test Treatment)0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Placebo0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
InfluenzaInfections and infestations0/60/61/60/6
Most frequent other events
Showing 10 of 31
Most frequent other events
EventCHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)Placebo
Lower Respiratory Tract InfectionInfections and infestations2/60/60/60/6
NasopharyngitisInfections and infestations0/62/60/61/6
DizzinessNervous system disorders2/60/60/60/6
HeadacheNervous system disorders0/60/62/61/6
HypertensionVascular disorders1/60/62/60/6
Supraventricular ExtrasystolesCardiac disorders0/60/60/61/6
Periorbital OedemaEye disorders1/60/60/60/6
DiarrhoeaGastrointestinal disorders0/60/61/61/6
NauseaGastrointestinal disorders0/60/60/61/6
VomitingGastrointestinal disorders0/60/61/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Mean60.7 ± 7.361.8 ± 8.058.7 ± 8.270.7 ± 4.163.0 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Female12508
Male541616
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White666624
More than one race00000
Unknown or Not Reported00000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Mean25.98 ± 2.1730.23 ± 3.6630.02 ± 4.1827.80 ± 1.9028.51 ± 3.42
Smoking status at screening
Smoking status at screening(Participants)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Tobacco: Ex-smoker333413
Tobacco: Non-smoker333211
E-cigarettes: Ex-smoker00000
E-cigarettes: Non-smoker666624
Duration of smoking
Duration of smoking(years)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Mean40.3 ± 7.833.7 ± 16.321.7 ± 5.724.5 ± 16.329.6 ± 13.5
Number of pack-years
Number of pack-years(pack-years)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Mean18.60 ± 8.7922.43 ± 18.6020.00 ± 7.0018.00 ± 13.9819.62 ± 11.43
Time since diagnosis
Time since diagnosis(years)CHF 10067 1000 mg (Test Treatment)CHF 10067 2000 mg (Test Treatment)CHF 10067 3000 mg (Test Treatment)PlaceboTotal
Median1.25 (0.6 to 4.1)0.79 (0.3 to 4.1)1.21 (0.0 to 4.4)1.40 (0.2 to 4.6)1.00 (0.0 to 4.6)

7 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • PHI University Clinic of Pulmonology and Allergology
    Skopje, 1000, North Macedonia
  • Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials
    Kyiv, 01135, Ukraine
  • Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2TH, United Kingdom
  • Royal Papworth Hospital NHSFT - Cambridge Biomedical Campus
    Cambridge, CB2 0AY, United Kingdom
  • University of Dundee, NHS Tayside - Ninewells Hospital & Medical School
    Dundee, DD1 9SY, United Kingdom
  • Interstitial Lung Disease Research - NHS Lothian - Royal Infirmary of Edinburgh,
    Edinburgh, EH16 4SA, United Kingdom
  • Liverpool Clinical Research Facility - Liverpool University Hospital Foundation Trust
    Liverpool, L7 8XP, United Kingdom
  • Medicines Evaluation Unit - The Langley Building
    Manchester, M23 9QZ, United Kingdom
  • University Hospital Southampton - Department of Respiratory Medicine
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jun 2024, 16 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2022
First posted
Aug 24, 2022
StartActual
Jan 25, 2023
Primary completionActual
Jun 17, 2024
CompletionActual
Jun 17, 2024
Results first posted
Aug 14, 2025
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05513950
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Jan 25, 2023
Primary completion
Jun 17, 2024
Completion
Jun 17, 2024
Results posted
Aug 14, 2025
Last update
Aug 14, 2025

Study contacts

Lisa Spencer
principal investigator · Liverpool University Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion